1,3-Butadiene (BD) is a genotoxic carcinogen that is bioactivated to at least two mutagenic metabolites: 1,2-epoxybutene (EB) and 1,2:3,4-diepoxybutane (DEB). We reported previously that lacI transgenic mice exposed to BD had an increased frequency of specific base substitution mutations in the bone marrow and spleen relative to unexposed controls. In the experiments described here, we determined the mutagenicity and mutational spectrum of EB in Rat2 lacI transgenic fibroblasts as a means of assessing the contribution of this metabolite to the lacI mutational spectrum of BD. Rat2 cells were exposed to 0, 0.4, 0.6, 0.8 or 1.0 mM EB for 24 h, resulting in a range of cell survival from 100 to 15%, respectively. Mutagenicity was assessed at 0, 0.6 and 1.0 mM EB. Unexposed controls had a background mutant frequency of 6 ⍨ 1 ⍨ 10 -5 , while the mutant frequency in cells exposed to 0.6 and 1.0 mM EB was increased 2-and 3-fold, respectively. DNA sequence analysis of 154 lacI mutants recovered in these experiments revealed an increase in the frequency of specific base substitution mutations in cells exposed to 1.0 mM EB compared with controls. These included G:C→A:T transitions at non-CpG sites, G:C→T:A transversions and A:T→T:A transversions, which have all been observed in lacI mutants isolated from transgenic mice exposed to BD. These results suggest that EB causes mutation primarily by base substitution and that the spectrum of these mutations closely resembles that of BD. These data, along with previous findings from our laboratory, suggest that EB is more likely than DEB to be primarily responsible for the lacI mutational spectrum observed in lacI transgenic mice exposed to BD.
Introduction
1,3-Butadiene (BD) is a gas used in the production of numerous plastics and resins and ranks in production among the top 20 synthetic organic chemicals in the USA (1) . BD is also a ubiquitous environmental contaminant, formed during hydrocarbon combustion, that is regulated as a hazardous air pollutant under the 1990 Clean Air Act Amendment (2) . Human exposure to significant levels of BD is likely to occur mainly in occupational settings. Prior to 1990, the 8 h time-weighted average (TWA) permissible exposure limit (PEL) for BD set by the Occupational Safety and Health Administration (OSHA) was 1000 p.p.m. However, in the mid-1980s several studies demonstrated that BD was a multiple organ carcinogen in B6C3F1 mice and Sprague-Dawley rats (3) (4) (5) (6) (7) (8) . Striking species differences were observed in the spectrum of tumors and carcinogenic potency of BD, with mice being far more sensitive than rats. These studies led to an increased sense of urgency to understand the effects of BD on humans. Early epidemiological studies of BD-exposed workers in the synthetic rubber industry were equivocal with respect to the risk of cancer mortality associated with BD exposure (9) (10) (11) (12) . However, recent epidemiological studies of synthetic rubber workers designed to address some of the shortcomings of the earlier work have found an association between long-term BD exposure and leukemia (13, 14) . In 1996, the OSHA lowered the 8 h TWA PEL for BD to 1 p.p.m. (15) .
The International Agency for Research on Cancer currently classifies BD as a probable human carcinogen (Group 2A) (16) . However, the National Toxicology Program has recommended that BD be upgraded to a known human carcinogen (17) . Due to its apparent carcinogenic potential and opportunity for exposure, BD has become a high priority for human risk assessment (18) .
The toxicology of BD has been reviewed extensively (19) (20) (21) . BD is bioactivated to at least two genotoxic metabolites: 1,2-epoxybutene (EB) and 1,2:3,4-diepoxybutane (DEB). EB and DEB are direct-acting mutagens in a number of in vitro systems (21) and both have been shown to produce several different types of genotoxic alteration in vivo (22) (23) (24) . Previous studies from our laboratory have investigated the mutagenicity and mutational spectrum of BD in B6C3F1 lacI transgenic (Big Blue) mice. We reported that inhalation exposure of Big Blue mice to 62.5, 625 or 1250 p.p.m. BD produced a dosedependent increase in the lacI mutant frequency in the bone marrow and spleen (25) (26) (27) . DNA sequence analysis of mutants recovered in that experiment revealed significant increases in the frequency of several base substitution mutations.
The goal of our current research is to understand the origin of this shift in mutational spectrum in BD-exposed mice by examining the lacI mutational spectra of the metabolites EB and DEB in Rat2 lacI transgenic fibroblasts (Big Blue rat cells). We recently reported that DEB induced micronuclei at levels that do not induce mutation at the lacI transgene in these cells (28) . This is likely due to the ability of DEB to produce large deletions that cannot be efficiently recovered in the Big Blue assay. In the present study, we report on the mutagenicity and mutational spectrum of EB at lacI in Rat2 cells in vitro. 
Materials and methods

Experimental system
The Big Blue Rat2 cells (Stratagene, La Jolla, CA) used in these experiments were constructed by co-transfection of the rat embryonic fibroblast cell line Rat2 with the λ lacI/αZ shuttle vector and the pSV2NEO plasmid (29) . The λ shuttle vector, which has integrated into the Rat2 genome at two sites (~60 copies/cell), is identical to that used to generate the Big Blue™ mouse. Cell culture Rat2 cells were cultured as a monolayer in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY) containing 2 mM L-glutamine, 60 IU/ml penicillin, 60 mg/ml streptomycin, 200 mg/ml geneticin (G418) (Gibco BRL) and 10% heat-inactivated defined fetal bovine serum (HyClone, Logan, UT) at 37°C in a humidified incubator (Forma Scientific, Marietta, OH) containing 10% CO 2 . Under these conditions, the average cell cycle time was~19 h. Low passage (Ͻ5) cells were used in each experiment. Cells were treated at 30-40% confluence (~2.5ϫ10 6 Cell pellets were stored at -80°C. Each pellet, containing~1.5-2 ϫ 10 6 viable cells and representing a single exposed flask, was considered the experimental unit. Mutant frequency determinations. Mutant frequency was assessed in cells exposed to 0.6 and 1.0 mM EB and in the medium, solvent and positive control cells from the two experiments. Genomic DNA was prepared from cell pellets using the Megapore method (SRI International, Menlo Park, CA). Cell pellets were thawed on ice and resuspended in 5 ml ice-cold cell lysis solution (CLS; 10 mM Tris-HCl, pH 8.3, 140 mM NaCl, 3 mM KCl, 0.35 M sucrose, 1 mM EDTA and 1% Triton X-100) for 5 min. These suspensions were filtered through a 100 µm nylon mesh filter into 50 ml tubes and centrifuged at 1100 g at 4°C for 12 min. The supernatant was removed, the pellet was rinsed with an additional 3 ml CLS and the centrifugation was repeated for 5 min. Following the second centrifugation, the supernatant was removed and the tubes were swabbed with a cotton swab to remove residual supernatant. The pellets were resuspended in 75 ml dounce buffer (Stratagene) and an equal volume of a proteinase K solution [2 mg/ml proteinase K (Sigma), 2% SDS, 100 mM EDTA] was added. The solutions were incubated at 50°C for 15 min and then transferred onto a 0.45 µm filter (Millipore) floating in a 100 mm Petri dish containing 35 ml TE buffer. After 18-20 h, the DNA was removed from the filters and stored at 4°C. The λ shuttle vector containing the lacI transgene was recovered from genomic DNA with λ phage packaging extract (Transpack; Stratagene) according to the manufacturer's instructions. Packaged phage were preadsorbed to Escherichia coli SCS-8 cells for 20 min at 37°C, mixed with prewarmed NZY top agar containing 1.3 mg/ml X-gal (dissolved in dimethylformamide) and poured into 22.3 cm/side square assay trays (Vangard International, Neptune, NJ) containing NZY agar. Plates were incubated at 37°C overnight.
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The total number of clear lacI ϩ plaques was estimated for each plate by counting three 6.25 cm 2 sections, averaging these numbers and multiplying by a scaling factor. Blue lacI -plaques were counted and picked into individual tubes containing 0.5 ml SM buffer and 50 µl chloroform for further characterization. All mutant plaques were confirmed by restreaking on an SCS-8 bacterial lawn growing on NZY top agar containing X-gal.
The lacI mutant frequency was calculated for each sample by dividing the number of confirmed mutant plaques by the total number of plaques analyzed. For each sample, Ͼ200 000 plaques were analyzed (Table I) . Analysis of variance (ANOVA) (α ϭ 0.05) was used to detect differences between treatment groups. A Dunnett's multiple comparison (30) was used to compare each treatment group with controls.
DNA sequence analysis of lacI mutants
The lacI gene was sequenced from lacI mutants isolated from solvent and medium control cells (collectively considered as background mutants) and from cells exposed to 1.0 mM EB. Mutants to be sequenced were selected from the two mutagenicity experiments such that they were distributed evenly among all of the independently exposed samples. Each mutant was purified by replating at low density on a 100 mm Petri dish. From each dish, a single isolated lacI -plaque was cored and placed into 50 µl deionized water and boiled for 15 min. Following centrifugation, the lacI gene was amplified using 5 µl supernatant from the boiled plaque as the DNA template in a PCR. The PCR products were purified with Wizard PCR preps (Promega, Madison, WI) according to the manufacturer's instructions, and visualized on a 1% agarose gel containing ethidium bromide. The PCR products were sequenced with a Taq DyeDeoxy Terminator sequencing kit on an Applied Biosystems 373 DNA sequencer (Applied Biosystems, Foster City, CA). The primers used for the PCR and sequencing of lacI have been published (25) . Sequence data were analyzed with Factura and AutoAssembler software (Applied Biosystems). Each lacI mutant was sequenced in its entirety and all mutations were determined by at least two primer reactions. The first G in the GTG start codon is base number 29.
Mutants were considered to be siblings if the same mutation occurred more than once in an independently exposed cell culture sample. In such a case, the first mutation, but not the siblings, was included in the analysis.
Statistical analysis of mutational spectra
To examine the mutational spectrum data in control and EB-exposed cells for differences, the mutation frequency for each group was calculated according to the 'effective size' method of Carr and Gorelick (31) . This method provides a basis for comparison when the DNA sequences of only a fraction of mutants in a given group have been determined. The category-specific mutation frequencies were calculated by dividing the number of mutations in a category (e.g. G:C→T:A) by the effective size (see Table IV ). Fisher's exact test (α ϭ 0.05) was used to test for significant differences between groups using the mutation frequency calculated for each particular genotypic change within mutants from control and EB-exposed cells. P-values obtained with Fisher's exact test were adjusted by a stepdown Bonferroni procedure (31, 32) to control the inflated false positive rate that results from performing multiple tests on data from a single experiment.
Results
EB cytotoxicity
Relative survival of Rat2 cells following exposure to a range of concentrations of EB was determined by recording their cumulative growth over a period of 7 days (168 h). Survival relative to medium controls was assessed as a percentage of the number of cells surviving at 120 h after plating. Exposure of Rat2 cells to 0.4, 0.6, 0.8, 1.0 or 1.2 mM EB resulted in 49, 31, 12, 10 and 5% survival, respectively, compared with medium controls (Figure 1) .
EB mutagenicity
The mutagenicity of EB at the lacI transgene in Rat2 cells was determined in two independent experiments. In the first experiment, cells exposed to medium only and to medium containing 0.1% DMSO (solvent control) had mean mutant frequencies (Ϯ SD) of 6.6 Ϯ 0.1 and 6.5 Ϯ 1.2ϫ10 -5 , respectively. Cells exposed to 0.6 and 1.0 mM EB had mutant frequencies of 13.2 Ϯ 3.2 and 18.6 Ϯ 1.8ϫ10 -5 , respectively (Table I) . These values represent increases of~2-and 3-fold over background, both of which were statistically significant (ANOVA, P ϭ 0.006).
In the second experiment, three replicates per exposure concentration were used. Medium and solvent controls had mutant frequencies similar to the controls in the first experiment (5.6 Ϯ 0.7 and 6.4 Ϯ 0.7ϫ10 -5 , respectively). A dose-response effect similar to that in the first experiment was seen in cells exposed to 0.6 and 1.0 mM EB (14.8 Ϯ 0.8 and 18.1 Ϯ 5.4ϫ10 -5 , respectively) (ANOVA, P ϭ 0.001).
DNA sequence analysis of lacI mutants
For determination of the mutational spectra in untreated cells and in cells exposed to EB, mutants from medium and solvent controls from both experiments were selected and collectively 1881 considered 'background'; mutants from cells exposed to 1.0 mM EB in both experiments were selected for the exposed group. Because the mutant frequency for this group is~3-fold that of controls,~2/3 mutants should be EB-induced.
Background lacI mutational spectrum in Rat2 cells
From the unexposed control cells, 86 mutants were analyzed by DNA sequencing. For 2/86 of these spontaneous mutants, no mutation was found within the amplified PCR product. Of the remaining 84 mutants, 72 (86%) were considered to be independent mutations. The types and locations of base substitution mutations are shown in Table II (indicated bases refer to the coding strand of the lacI gene); complex mutations, insertions and deletions are shown in Table III ; the 'effective size' calculation used to determine the frequency of mutations in different categories is shown in Table IV ; the overall spontaneous mutational spectrum, including category-specific mutation frequencies, is summarized in Table V. Single base substitution mutations accounted for 79% of all background mutations. Fifty-two of seventy-three (72%) of the background mutations occurred at G:C base pairs, while 6/72 (8%) occurred at A:T base pairs. G:C→A:T transitions accounted for 24/72 (33%) of the background mutations, with 20 of those 24 occurring at 5Ј-CpG-3Ј sites. This category of mutation typically makes a larger contribution to the background mutational spectrum at lacI. However, a single mutation (G588→T) was recovered in 21 sequenced mutants; 11 of these were considered siblings and excluded from the analysis. This mutation was counted once for each independently exposed sample in which it occurred (10 occurrences), which made the contribution of G:C→T:A transversions unusually high at 20/72 (28%). G:C→C:G transversions accounted for 8/72 (11%) of the background lacI mutations. Of the mutations at A:T base pairs, 3/72 (4%) were A:T→G:C transitions, 1/72 (1%) was an A:T→C:G transversion and 2/72 (3%) were A:T→T:A transversions. From the 72 independent background mutants analyzed, 15 (20%) deletions, insertions or complex mutations were recovered (Table III) . Most of these were insertions or deletions of a single base resulting in frameshift mutations. lacI mutational spectrum in EB-exposed cells From the cells exposed to 1.0 mM EB, 72 mutants were analyzed by DNA sequencing. As with the background mutants, 2/72 of the EB mutants contained no mutation within the amplified PCR product. One mutant was found to have two mutations. From the 70 mutants, 68 independent mutations were found. Sixty-two of sixty-eight (91%) of the independent mutations in EB-exposed cells were base substitution mutations. Of these mutations, 41/68 (60%) occurred at G:C base pairs. Mutations at A:T base pairs occurred in 21/68 (31%) of the EB mutants analyzed. G:C→A:T transitions accounted for 11/68 (16%) of the EB mutants. In contrast to the background mutants, in which most of these mutations occurred at 5Ј-CpG-3Ј sites, the majority of G:C→A:T transitions in EB mutants (9/11) occurred at non-5Ј-CpG-3Ј sites. The frequency of these mutations in the EB-exposed cells was significantly increased (P ϭ 0.003) when compared with controls (Table V) . G:C→T:A transversions accounted for 22/68 (32%) of the EB mutants. This represents 1884 a significant increase (P Ͻ 0.0001) in the frequency of these mutations in the EB mutants compared with the background mutants. There was a significant increase (P ϭ 0.005) in the frequency of A:T→C:G transversions among the EB mutants (6/68, 9%) compared with background mutants (1/71, 1%). In addition, the frequency of A:T→T:A transversions was significantly increased (P Ͻ 0.0001) among the EB-induced mutants (11/68, 16%) compared with background mutants (2/ 71, 3%).
Analysis of the 68 mutations from EB-exposed cells revealed six (9%) insertions, deletions or complex mutations, compared with 13/71 (18%) such events in the background mutants (Table V) .
Discussion
In this study, Rat2 lacI transgenic fibroblasts were exposed to EB in an effort to understand how it may contribute to the mutational spectrum of BD at the lacI transgene in vivo. Mutagenicity experiments demonstrated that exposure of Rat2 cells to 0.6 and 1.0 mM EB for 24 h resulted in a 2-and 3-fold increase in mutant frequency, respectively, compared with controls. These results suggested that EB was acting through a different mechanism than DEB, which did not increase the lacI mutant frequency in these cells (27) . The failure of DEB to increase the lacI mutant frequency is likely due to its propensity to produce large deletions that cannot be recovered with this assay (33) . The ability of EB to induce mutants in this system suggested that it was acting primarily through base substitution mutations.
DNA sequence analysis of mutants recovered in the mutagenicity experiments revealed that 79% of the background mutations and 91% of the EB-induced mutations were base substitution mutations. DNA sequencing also revealed a single mutation (G588→T) that occurred at a high frequency (25%) in all the spontaneous samples (medium and solvent controls). If the spontaneous lacI mutant frequency were corrected for the frequency of this mutation, it would be lowered from 6.3 to 4.7ϫ10 -5 , both of which are in the range of background In the mutants recovered from cells exposed to 1.0 mM EB, this mutation was found in 4/5 independently exposed samples. However, it constituted only 8.7% of the EB mutants,~3-fold lower than in the background mutants and inversely proportional to the fold increase in the mutant frequency. This suggests that this G588→T was a mutation that arose spontaneously early in the stock of our Rat2 cells and is not a hotspot for spontaneous mutation. In addition, there are no reports of this mutation occurring in other cultures of Rat2 cells, which suggests that the mutation is unique to our cell line. However, this example illustrates a significant concern when using this type of cell culture system. Since cells in culture are constantly dividing, the risk of replicating spontaneous mutations is very high and there is no easy way to select against spontaneous mutants while cells are in culture. We had established criteria for the exclusion of mutant siblings before this mutation was discovered; therefore, we included in the analysis one of these G588→T mutations per independently exposed sample in which it occurred. The background lacI mutational spectrum generated in these experiments is consistent with previously reported background mutational spectra in Rat2 cells (34, 35) and with spectra from untreated lacI transgenic mice (25, 36, 37) . Specifically, G:C→A:T transitions are the predominant mutation in the background spectrum. A large number (20/24) of these occur at 5Ј-CpG-3Ј dinucleotides. Methylation of cytosine residues at these CpG sites in the lacI transgene by mammalian DNA methylases and subsequent deamination of these 5-methylcytosine residues can result in G:C→A:T transitions following DNA replication (25, 36) . Other base substitution mutations occurred at frequencies comparable with other published reports (25, 36, 37) .
The spectrum of lacI mutations from EB mutants was quite different from the background lacI spectrum. In contrast to the low frequency of G:C→A:T transitions that occurred at non-CpG sites in control cells, there was an increased frequency of these mutations in EB-exposed cells. A similar increase in the frequency of this mutation was also seen in the bone marrow and spleen of lacI mice following exposure to 1250 p.p.m. BD (26, 27) . The frequency of G:C→T:A transversions was also increased in EB-exposed cells compared with controls. A similar induced mutation frequency was observed in the spleen of lacI mice exposed to BD (27) .
There was an increase in the frequency of mutations at A:T base pairs in EB mutants compared with background mutants. This increase in mutant frequency can be attributed primarily to two categories of mutation. The frequency of A:T→C:G transversions was increased in EB-exposed cells relative to controls. However, the frequency of this particular mutation has not been found to increase following exposure to BD (25) (26) (27) . One of the most significant differences in the background and EB spectra was the increased frequency of A:T→T:A transversions in cells exposed to EB compared with control cells. An increased frequency of A:T→T:A transversions was observed in lacI mutants recovered from the spleen and bone marrow of lacI mice exposed to 625 or 1250 p.p.m. BD (25) (26) (27) 38) . In addition, this mutation was also increased at hprt in human TK6 lymphoblasts exposed to EB (39) , making it the most consistent change observed following exposure to BD or EB both in vitro and in vivo. Results from these experiments add to the evidence for a role of EB in producing many of the same mutations observed previously in lacI mice exposed to BD.
While many BD-and EB-derived DNA adducts have been identified (40) (41) (42) (43) (44) (45) (46) (47) (48) , the specific mutagenic lesions leading to the EB-mediated mutations at lacI and hprt have not yet been determined. In vitro and in vivo evidence suggests that the most readily formed BD and EB adducts include α,β-N 7 -guanosine and β-N 6 -adenosine (44) (45) (46) . The formation of N 6 -ethenoadenine adducts has been implicated in specific A:T→T:A transversions found in the tumor suppresser gene p53 in liver angiosarcomas from vinyl chloride-exposed factory workers (47, 48) . In addition, an N 3 -thymidine adduct of EB formed in smaller amounts has also been identified (49) . These adducts are extremely stable and 3-ethylthymidine has been shown to mispair with dT during in vitro DNA replication, resulting in A:T→T:A transversions, making it a potentially important mutagenic precursor (50) .
Since bioactivation of BD can lead to at least two genotoxic metabolites, studies in our laboratory have attempted to evaluate the mutagenicity and mutational spectrum of each metabolite independently to assess its role in mediating the in vivo mutagenicity and mutational spectrum of the parent compound BD. Previously, we determined that DEB was an effective inducer of micronuclei in Rat2 cells but did not induce mutations that could be recovered in the Big Blue Rat2 assay system (28) . In the present study, we determined that EB produces increases in the frequency of specific base substitution mutations in Rat2 cells similar to those observed in lacI mice exposed to BD (25, 26) . These studies have shown that the mechanism of mutagenicity of EB and DEB and the spectrum of mutations they induce are distinct. In Rat2 cells, EB is more effective at inducing single base substitutions, while DEB is effective in the induction of chromosomal alterations. These results are consistent with the roles of EB and DEB in mutation of the hprt gene in human TK6 cells (39, 51) . Which of these two metabolites is ultimately responsible for the in vivo genotoxic effects of BD remains uncertain. However, EB is evidently the major contributor to the lacI mutational spectrum of BD in transgenic mice.
